These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 19771745)

  • 1. [The I-PRESERVE study].
    Trimarco B; Rosei EA
    G Ital Cardiol (Rome); 2009 Aug; 10(8):495-8. PubMed ID: 19771745
    [No Abstract]   [Full Text] [Related]  

  • 2. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy.
    Cardiovasc J Afr; 2008; 19(6):337-8, discussion 339. PubMed ID: 19104736
    [No Abstract]   [Full Text] [Related]  

  • 3. Irbesartan for heart failure with preserved ejection fraction.
    Amato JL; Amato JL
    N Engl J Med; 2009 Mar; 360(12):1256-7; author reply 1258-9. PubMed ID: 19297582
    [No Abstract]   [Full Text] [Related]  

  • 4. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
    Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
    J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Irbasartan in patients with hart failure and preserved left-ventricular systolic function. Results of the I-PRESERVE study].
    Preobrazhenksiĭ DV
    Kardiologiia; 2009; 49(2):80. PubMed ID: 19254224
    [No Abstract]   [Full Text] [Related]  

  • 6. CHARM study in CHF patients with impaired LV function reinforces benefits of candesartan cilexetil (Atacand).
    Cardiovasc J S Afr; 2004; 15(5):252. PubMed ID: 15483738
    [No Abstract]   [Full Text] [Related]  

  • 7. Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
    Pitt B
    Nat Clin Pract Cardiovasc Med; 2005 Feb; 2(2):70-1. PubMed ID: 16265371
    [No Abstract]   [Full Text] [Related]  

  • 8. Irbesartan for heart failure with preserved ejection fraction.
    Tomoda H
    N Engl J Med; 2009 Mar; 360(12):1257-8; author reply 1258-9. PubMed ID: 19301449
    [No Abstract]   [Full Text] [Related]  

  • 9. Irbesartan for heart failure with preserved ejection fraction.
    Schillaci G; Pucci G; Pirro M
    N Engl J Med; 2009 Mar; 360(12):1258; author reply 1258-9. PubMed ID: 19301450
    [No Abstract]   [Full Text] [Related]  

  • 10. Irbesartan for heart failure with preserved ejection fraction.
    Ghali JK
    N Engl J Med; 2009 Mar; 360(12):1257; author reply 1258-9. PubMed ID: 19301448
    [No Abstract]   [Full Text] [Related]  

  • 11. Assessment of long-term effects of irbesartan on heart failure with preserved ejection fraction as measured by the minnesota living with heart failure questionnaire in the irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial.
    Rector TS; Carson PE; Anand IS; McMurray JJ; Zile MR; McKelvie RS; Komajda M; Kuskowski M; Massie BM;
    Circ Heart Fail; 2012 Mar; 5(2):217-25. PubMed ID: 22267751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
    Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
    Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can brain natriuretic peptide be used to guide the management of patients with heart failure and a preserved ejection fraction? The wrong way to identify new treatments for a nonexistent disease.
    Packer M
    Circ Heart Fail; 2011 Sep; 4(5):538-40. PubMed ID: 21934089
    [No Abstract]   [Full Text] [Related]  

  • 14. Val-HeFT: do angiotensin-receptor blockers benefit heart failure patients already receiving ACE inhibitor therapy?
    McMurray JJ
    Nat Clin Pract Cardiovasc Med; 2005 Mar; 2(3):128-9. PubMed ID: 16265452
    [No Abstract]   [Full Text] [Related]  

  • 15. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
    Kum LC; Yip GW; Lee PW; Lam YY; Wu EB; Chan AK; Fung JW; Chan JY; Zhang Q; Kong SL; Yu CM
    Int J Cardiol; 2008 Mar; 125(1):16-21. PubMed ID: 17433840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin receptor blockers in heart failure. CHARM Study].
    Kochsiek K
    Internist (Berl); 2004 Sep; 45(9):1063-7. PubMed ID: 15309315
    [No Abstract]   [Full Text] [Related]  

  • 17. Renin-Angiotensin system blockade and worsening renal function in heart failure: an unfinished story.
    Metra M; Lombardi C
    J Am Coll Cardiol; 2014 Sep; 64(11):1114-6. PubMed ID: 25212645
    [No Abstract]   [Full Text] [Related]  

  • 18. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
    Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
    J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
    Miller AB; Piña IL
    Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
    Tepper D
    Congest Heart Fail; 2002; 8(1):57-8. PubMed ID: 11821630
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.